{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 10 of 122', '9.1.3 FAQL-PB Questionnaire', '72', '9.1.4', 'HADS Questionnaire', '72', '9.1.5 EQ-5D Questionnaires', '72', '9.1.6 Assessments of Control and Confidence', '72', '9.1.7 Global Assessments of HRQOL', '73', '9.1.8 Assessments of Food Challenge Outcomes', '73', '9.1.9 TSQM-9 Questionnaire', '73', '9.1.10 Exit Questionnaire', '73', '9.1.11 Qualitative Exit Interview', '73', '9.2 Measures of Desensitization', '74', '9.2.1 Skin Prick Test', '74', '9.2.2 Open-Label Food Challenge', '74', '9.2.3 Real-World Peanut Challenge', '74', '9.3', 'Safety and Other Assessments', '74', '9.3.1 Lung Function Tests and Assessments of Asthma Control', '74', '9.3.2 TNSS Questionnaires', '77', '9.3.3', 'SCORAD Index', '77', '9.3.4 PEESS v2.0 Questionnaire', '77', '9.3.5 Physical Examinations and Vital Signs', '77', '10 STATISTICAL METHODS', '78', '10.1 Statistical and Analytical Plans', '78', '10.2 Analysis Populations', '78', '10.3 Determination of Sample Size', '79', '10.4 Interim Analyses', '79', '10.5 Analyses of HRQOL', '79', '10.6 Analysis of Other Questionnaires', '81', '10.7 Analysis of Efficacy', '81', '10.8 Analysis of Safety', '82', '10.9 Other Analyses', '83', '11 STUDY COMMITTEES AND COMMUNICATIONS', '84', '12 LABORATORY REQUIREMENTS', '84', '12.1 Clinical Laboratory Tests', '84', '12.2 Basophil Activation Test', '85', '13 INVESTIGATOR AND ADMINISTRATIVE REQUIREMENTS', '85', '13.1 Ethics', '85', '13.1.1 Ethics Committee', '85', '13.1.2 Ethical Conduct of the Study', '86', '13.1.3 Subject Information and Informed Consent and Assent', '86', '13.1.4 Maintaining Subject Confidentiality', '86', '13.2 Data Quality Assurance', '86', '13.2.1 Data Management', '86', '13.2.2 Case Report Forms', '87', '13.2.3 Study Monitoring', '87', '13.2.4 Study Audits', '87', '13.3 Investigational Product Accountability', '88', '13.4 Retention of Records', '89', '13.5 Protocol Deviations', '89']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 11 of 122', '13.6 Study Termination', '89', '14 USE OF STUDY INFORMATION AND PUBLICATION', '90', '15 REFERENCES', '92', '16 INVESTIGATOR SIGNATURE', '95', 'LIST OF TABLES', 'Table 1:', 'Order of Subject and Parent/Caregiver Questionnaires To Be Completed', '30', 'Table 2:', 'AR101 Single Doses and Cumulative Dose on Day 1', '32', 'Table 3:', 'Initial Dose-Escalation Day 1 Procedures', '33', 'Table 4:', 'Up-Dosing Dose-Escalation Schedule (3-300 mg)', '34', 'Table 5:', 'Primary Reasons for Early Discontinuation', '37', 'Table 6:', 'Follow-Up HRQOL Questionnaires for Subjects Receiving AR101 Treatment Who', 'Discontinue Early', '39', 'Table 7:', 'Prohibited Medications', '45', 'Table 8:', 'Criteria for Serious Adverse Events', '47', 'Table 9:', 'CoFAR Severity Grading System for Allergic Reactions', '48', 'Table 10:', 'EAACI Severity Grading System for Anaphylaxis', '49', 'Table 11:', 'NCI CTCAE Severity Grading System for Adverse Events', '49', 'Table 12:', 'Allergy Symptom Severity and Study Product Dose Tolerability', '52', 'Table 13:', 'Description of Actions to Be Taken With Study Product Dosing for Allergy Symptoms on', 'Initial Dose-Escalation Day 1', '55', 'Table 14:', 'Description of Actions to Be Taken With Study Product Dosing for Allergy Symptoms', 'During Up-Dosing and Maintenance', '58', 'Table 15:', 'Dose Adjustment of Study Product After Treatment With Antihistamines and Epinephrine for', 'Dose-Related Allergy Symptoms During Up-Dosing and Maintenance', '60', 'Table 16:', 'Study Product Dose Re-Escalation After Dose Reduction for Reasons Other Than Allergic', 'Reactions', '61', 'Table 17:', 'Procedures for Missed Consecutive Doses of Study Product', '62', 'Table 18:', 'Summary of Instruments for Subject- and Parent/Caregiver-Reported HRQOL and Other', 'Outcomes', '70', 'Table 19:', 'Evaluation of Asthma Based on NHLBI Criteria', '76', 'Table 20:', 'Clinical Laboratory Tests', '84', 'LIST OF FIGURES', 'Figure 1:', 'Study Schematic', '24', 'Figure 2:', 'Management of Study Product Dosing for Allergy Symptoms on Initial Dose-Escalation', 'Day 1', '54', 'Figure 3:', 'Management of Study Product Dosing for Allergy Symptoms During Up-Dosing and', 'Maintenance', '57', 'Figure 4:', 'Adverse Event Reporting Period', '66', 'LIST OF APPENDICES', 'Appendix 1: Open-Label Food Challenge Procedures', '96']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 12 of 122', 'Appendix 2: Real-World Food Challenge Procedures', '104', 'Appendix 3: Study Schedule of Activities for All Subjects: Screening (Days -28 to -1)', '110', 'Appendix 4: Study Schedule of Activities for AR101 Treatment: Initial Dose Escalation and Up-Dosing', '112', 'Appendix 5: Study Schedule of Activities for AR101 Treatment: Maintenance', '115', 'Appendix 6: Study Schedule of Activities for Standard of Care Alone', '119', 'Appendix 7: Study Schedule of Activities for Subjects Who Discontinue Treatment Early or Exit With', 'Ongoing Adverse Event: Safety Follow-Up', '122']", "completion": ""}